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Stromal cell–derived factor (SDF-1), a member 
of the superfamily of chemoattractant cytokines 
known as chemokines, is a key regulator of B 
cell lymphopoiesis (1, 2), hematopoietic stem 
cell mobilization (3), and leukocyte migration. 
In mice genetically deleted of SDF-1 (1), early 
stage embryos exhibit profound defects in the 
formation of large vessels, as well as other mor-
phological anomalies such as septal malforma-
tion during cardiac development and abnormal 
brain patterning, including a disorganized cer-
ebellum (1). Ultimately, embryonic lethality is 
observed typically between days 15 and 18 of 
gestation. Several other reports demonstrate that 
SDF-1 can induce angiogenesis in a variety of 
ex vivo and in vivo models (4, 5).
SDF-1 has been thought to mediate all of 
these functions exclusively via a single cell sur-
face receptor known as chemokine receptor 4 
(CXCR4) (6). There are multiple shared bio-
logical functions of SDF-1 and CXCR4, with 
animals bearing CXCR4−/− and SDF-1−/− ge-
netic mutations manifesting overlapping phe-
notypic features and exhibiting embryonic 
lethality at approximately the same point in 
  fetal development (1, 2, 7). CXCR4 is a core-
ceptor for HIV (8, 9), and SDF-1 blocks HIV 
viral entry (6). Moreover, both SDF-1 and 
CXCR4 have been implicated in tumor cell 
metastasis (10) and proliferation (11–13), and 
CXCR4 antagonism blocks in vivo growth of 
several tumors (13).
We have previously reported (14) that SDF-1 
binds a second receptor, which we assigned the 
temporary designation of CCX-CKR2 until 
further characterization was obtained. The pres-
ent study reports on the use of cellular, molec-
ular, biological, and pharmacological approaches 
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to extensively characterize CCX-CKR2. The results reveal a 
previously unknown mechanism by which SDF-1 functions 
that is separate from the classical SDF-1–CXCR4 pathway. 
With an expanded understanding of CCX-CKR2 properties, 
we now rename this receptor CXCR7 and provide evidence 
for its role in oncologic processes.
RESULTS
Evidence for a novel SDF-1 binding protein
SDF-1– and CXCR4-defi  cient mice share the phenotype of 
embryonic lethality occurring around embryonic days 15–18 
(E15–18) of gestation (1, 2, 7), clearly establishing a critical 
role for both proteins in embryonic development. To better 
understand the role of SDF-1/CXCR4 in early develop-
ment, we further explored the consequences of CXCR4 gene 
deletion in mice before the E15–18 lethality event. How-
ever, experiments designed to characterize the wild-type, 
heterozygous, and homozygous mice in our CXCR4−/− col-
ony (7) unexpectedly revealed comparable binding of radio-
labeled SDF-1 by E13 fetal liver cells obtained from all three 
mouse groups (Fig. 1 A).
Consistent with these observations using cells from 
CXCR4-defi  cient mice, separate experiments revealed dis-
crepancies between CXCR4 expression and SDF-1 binding 
on diff  erent cell lines. Several tumor cell lines, including the 
breast tumor cell line MCF-7, bound 125I SDF-1 with excep-
tionally high affi   nity ( 200 pM; Fig. 1 B, top middle) but 
did not stain with the commercially available anti-CXCR4 
mAb 12G5 (Fig.1 B, top left), nor did cells mobilize calcium 
(Fig. 1 B, top right) or migrate (not depicted) in response to 
SDF-1. In contrast, a transformed T cell line, CEM-NKr, 
exhib  ited more typical characteristics of CXCR4 expression, 
namely high affi   nity binding to 125I SDF-1 (IC50  1.8 nM; 
Fig. 1 B, bottom middle), good reactivity with anti-CXCR4 
mAb (Fig.1 B, bottom left), and both a robust increase in 
  cytosolic calcium levels (Fig. 1 B, bottom right) and specifi  c 
migration (not depicted) in response to SDF-1. These data 
suggested that functional CXCR4 protein was not expressed 
on the MCF-7 cell surface and revealed a previously unrec-
ognized pattern of SDF-1 activity. In addition, the data indi-
cated that, in some cases, SDF-1 interacts diff  erently with 
diff  erent cell types, with CEM-NKr and MCF-7  exemplifying 
the contrasting behaviors.
We tested  100,000 “small molecule” organic com-
pounds for their ability to inhibit binding of 125I SDF-1 to 
  either CEM-NKr or MCF-7 cells. One compound that in-
hibited SDF-1 binding to MCF-7 cells, but not to CEM-
NKr cells, was optimized chemically, yielding an SDF-1 
binding antagonist designated CCX451 (14). CCX451 in-
hibited binding of 125I SDF-1 to MCF-7 cells with high 
  affi   nity ( 5 nM; Fig.1 C, top, closed squares) but did not 
  inhibit binding of 125I SDF-1 to CEM-NKr cells (Fig. 1 C, 
bottom, closed squares). In contrast, another small molecule, 
AMD3100, known to specifi  cally inhibit SDF-1 binding to 
CXCR4 (15) was shown to have the inverse pattern of inhi-
bition; it inhibited binding of 125I SDF-1 to CEM-NKr cells 
but not to MCF-7 cells (Fig. 1 C, open circles). Consistent 
with these binding data, AMD3100 inhibited all functions of 
Figure 1.  Evidence for a novel SDF-1 binding protein. (A) 125I SDF-1 
binds to E13 fetal liver from wild-type (CXCR4+/+), heterozygous (CXCR4+/−), 
and homozygous (CXCR4−/−) mouse embryos. In each case, binding speci-
fi  city is demonstrated by the ability of 100 nM of unlabeled SDF-1α to 
effectively compete radiolabeled ligand binding to fetal liver calls. Data 
represent the means of three determinations ± SD. (B) FACS analysis of 
CXCR4 expression with the anti-CXCR4 mAb 12G5 (left), assessment of 
radiolabeled 125I SDF-1 binding (middle), and 10 nM SDF-1–induced 
  calcium mobilization (right) using MCF-7 cells (top) or CEM-NKr cells 
(bottom). FACS histogram indicates isotype control (open) and specifi  c 
staining (shaded). Arrows indicate ligand (SDF-1α) addition to cells. This 
set of analyses has been reproduced in at least 10 independent studies, 
and error bars represent SEM. (C) SDF-1 binding site on MCF-7 cells is 
pharmacologically distinct from CXCR4. 125I SDF-1 binding to CEM-NKr 
and MCF-7 cells is performed in the presence of SDF-1α, CXCR7 antago-
nist CCX451, or CXCR4 antagonist AMD3100. Error bars represent SEM.JEM VOL. 203, September 4, 2006  2203 
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Figure 2.  The novel SDF-1/I-TAC binding protein is RDC1. 
(A) Binding of 125I SDF-1 or 125I I-TAC to MCF-7 cells was effectively com-
peted using either unlabeled SDF-1 or unlabeled I-TAC. Error bars repre-
sent SEM. (B) Binding of 125I SDF-1 to either human breast tumor MDA 
MB 435s wild-type cells (top) or MDA MB 435s transfected with CXCR7 
(bottom) in the presence of increasing concentrations of SDF-1α, I-TAC, 
CXCR7 antagonist CCX451, and CXCR4 antagonist AMD3100. Total counts 
bound for each condition are shown and represent the mean of four de-
terminations ± SD. RDC1 Homo sapiens is available from GenBank/EMBL/
DDBJ under accession no. P25106. (C) Mouse mAb to human CXCR7 (11G8) 
binds MDA MB 435s cells transfected with CXCR7 (right) but not MDA 
MB 435s wild-type cells (left). FACS histogram indicates isotype control 
(open) and specifi  c staining (shaded). (D) Mouse anti–human CXCR7 mAbs 
11G8 and 6E10 but not irrelevant isotype control, 11H3, largely inhibit 
binding of radiolabeled SDF-1 (top) or I-TAC (bottom) to CXCR7 transfec-
tants. Error bars represent SEM. Data shown in (C) and (D) have been 
  obtained in at least fi  ve experiments, and the percent inhibition relative to 
untreated controls (total bound) is shown.2204   A NOVEL SDF-1/I-TAC RECEPTOR INVOLVED IN TUMORIGENESIS | Burns et al.
Figure 3.  Expression of CXCR7 by transformed human and mouse 
cell lines. (A) Membrane CXCR7 and CXCR4 expression on mouse B cell 
lymphoma, BCL1, and human cervical carcinoma HeLa cells is demon-
strated by anti-CXCR7 antibody 11G8 staining and anti-CXCR4 antibody 
12G5. Staining is represented as shaded versus open for isotype control. 
(B) 125I SDF-1 binding profi  le reveals membrane CXCR7 expression on 
BCL1 and HeLa cell surfaces. CXCR7 binding is defi  ned by inhibition of 
the 125I SDF-1 binding with 100 nM of nonradiolabeled ligand or 10 μM 
CXCR7 antagonist CCX451, but not by 10 μM CXCR4 antagonist 
AMD3100. Error bars represent SEM. (C) Northern blot analysis of mRNA 
expression of CXCR7 and CXCR4 in a panel of human transformed 
cell lines.
SDF-1 on CEM-NKr cells (i.e., calcium mobilization 
and cell migration), whereas CCX451 had no eff  ect (unpublished 
data). CCX451 did not aff  ect the binding of any other 
known CXCR to its specifi  c chemokine ligand (CXCL; 
  unpublished data).
To explore the specifi  city of SDF-1 binding to the MCF-7 
and CEM-NKr cell lines, we used a comprehensive competi-
tion binding approach described in detail elsewhere (16). 
  Using 125I SDF-1 as the “signature” ligand, the ability of >90 
discrete chemokines and chemokine variants to displace the 
binding of SDF-1 to CEM-NKr and MCF-7 cells was inves-
tigated. On CEM-NKr cells, only SDF-1 and the human 
herpes virus 8–encoded chemokine vMIP-II (known to bind 
CXCR4) (17) were eff  ective competitors (unpublished data). 
In contrast, a previously unknown binding pattern was ob-
served on MCF-7 cells, where in addition to SDF-1 and 
vMIP-II, the CXC chemokine interferon-inducible T cell α 
chemoattractant (I-TAC; also known as CXCL11) strongly 
displaced 125I SDF-1 binding (Fig. 2 A, top). Similarly, when 
125I I-TAC was used as the signature ligand, it bound to and 
was displaced from MCF-7 cells by unlabeled SDF-1 (Fig. 
2 A, bottom).
Previously I-TAC, as well as two other chemokines, Mig 
(CXCL9) and IP10 (CXCL10), had been thought to bind 
only CXCR3 (18, 19). However, the MCF-7 cells used in 
these studies expressed neither CXCR3 protein nor mRNA 
(unpublished data). Furthermore, IP10 and Mig had no in-
hibitory eff  ect on the binding of 125I SDF-1 or 125I I-TAC to 
the MCF-7 cells (unpublished data). Like 125I SDF-1, 125I I-
TAC binding to MCF-7 was inhibited by CCX451 but not 
AMD3100 (unpublished data), and I-TAC failed to induce 
either calcium mobilization in or migration of MCF-7 cells. 
CCX451 did not inhibit the binding of 125I I-TAC to a cell 
transfectant expressing CXCR3 and lacking SDF-1 binding 
sites (unpublished data). Competitive binding analysis of 
SDF-1 on the CEM-NKr cells showed low nM affi   nities in 
all cases (Figs. 1 C and 2 A). However, SDF-1 consistently 
bound to the MCF-7 cells with a  20-fold higher affi   nity 
than that of I-TAC binding to MCF-7 cells or SDF-1 bind-
ing to CEM-NKr cells; i.e.,  100–200 pM versus 2–5 nM, 
respectively (Fig. 1 B, middle panels).
The novel SDF-1/ITAC-1 binding protein 
is the 7-transmembrane receptor RDC1
To identify the molecular nature of the new SDF-1/I-TAC 
binding site, we used the signature binding characteristics de-
fi  ned in the previous section; i.e., 125I SDF-1 binding that 
could be inhibited by I-TAC and CCX451 but not by 
AMD3100. Among other strategies, our search included eval-
uation of “orphan” G protein–coupled receptors (GPCRs), 
which by predicted amino acid sequence looked structurally 
similar to CXCRs (for review see reference 20). One orphan, 
RDC1 (21, 22), was introduced into the human breast tumor–
derived cell line MDA MB 435s, which lacks both CXCR4 JEM VOL. 203, September 4, 2006  2205 
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and RDC1 mRNA (not depicted) and also lacks the ability 
to bind 125I SDF-1 (Fig. 2 B). In contrast to the wild-type line, 
the RDC1 transfectant possessed the capacity for specifi  c high 
affi   nity SDF-1 binding; this binding could be blocked by 
I-TAC and CCX451 but not by AMD3100 (Fig. 2 B), exhib-
iting affi   nities commensurate with those seen on MCF-7 cells 
(Fig. 2 A). Identical ligand binding properties were observed 
using a second polyclonal RDC1 transfected cell line, as well 
as 293 cells that had been transfected with RDC1 but not 
  parental 293 cells (not depicted).
The RDC1 gene product was serologically distinct from 
both CXCR4 and CXCR3, as specifi  c antibodies to these 
receptors failed to bind RDC1-transfected cells (unpublished 
data). In contrast, mAbs produced by genetic immunization 
of mice with a plasmid-encoding human RDC1 specifi  cally 
bound to the RDC1 transfectant but not to the wild-type 
MDA-MB 435s cells (Fig. 2 C). Separate experiments showed 
the anti-RDC1 antibodies bound to two separate polyclonal 
lines of MBA-MB 435s cells transfected with RDC1, as well 
as 293 cells transfected with RDC1, but did not bind to 
MBA-MB 435s cells or 293 cells that had been mock trans-
fected or transfected with another CXCR (unpublished data). 
Anti-RDC1 hybridoma supernatants 11G8 or 6E10 but not 
an unrelated isotype control antibody, 11H3, specifi  cally in-
hibited binding of both 125I SDF-1 and 125I I-TAC to the 
RDC1 transfectants in a manner similar to that of the small 
molecule antagonist CCX754, a CCX451 analogue (Fig. 2 D). 
In subsequent experiments, higher concentrations of purifi  ed 
preparations of 11G8 and 6E10 mAbs completely neutralized 
ligand binding, further validating the reagents’ specifi  city 
(unpublished data). Collectively, these data indicate that the 
RDC1-encoded protein contains an SDF-1 binding site with 
properties that are indistinguishable from the novel SDF-1/
I-TAC binding site expressed on MCF-7 cells (Figs. 1 and 2). 
We provisionally designate the RDC1 gene product as 
CXCR7 for the seventh receptor identifi  ed to date for che-
mokines belonging in the CXC class.
Preferential expression of CXCR7 by transformed cells 
and during embryonic development
Our initial characterization of CXCR7 expression revealed 
that many of the human and mouse transformed cell types 
Figure 4.  Nontransformed human and mouse tissues express little 
membrane CXCR7 but frequently express CXCR7 by Northern blot 
analysis. (A) Binding of 125I SDF-1 to various tissue cells obtained from 
the mouse. Error bars represent SEM (B) Anti-CXCR7 antibody 11G8 fails 
to bind mouse blood, liver, lung, or heart cells. FACS histogram indicates 
isotype control (open) and specifi  c staining (shaded). (C) Northern blot 
analysis shows CXCR7-specifi  c mRNA in normal mouse tissues, but this 
does not correlate with cell surface protein expression.2206   A NOVEL SDF-1/I-TAC RECEPTOR INVOLVED IN TUMORIGENESIS | Burns et al.
we tested (e.g., MCF-7 breast tumor, HeLa cervical carci-
noma, and BCL1 lymphoma are reported in this paper, 
whereas T98G glioma, A549 lung carcinoma, and 4T1 
breast tumor are unpublished data) were abundantly posi-
tive for expression of CXCR7 protein (Fig. 3). This conclu-
sion was evident when CXCR7 expression was evaluated 
by any of several techniques; e.g., fl  ow cytometric staining 
with the anti-CXCR7 mAb (Fig. 3 A), 125I SDF-1 binding 
that could be inhibited by ITAC and CCX451 but not by 
AMD3100 (Fig. 3 B), and by Northern blot analysis of 
CXCR7 mRNA levels (Fig. 3 C). Importantly for these 
experiments, the anti–human CXCR7 antibody also bound 
mouse CXCR7 on mouse tumor lines and cell lines trans-
fected with mouse CXCR7 (Fig. 3 A and not depicted). 
CXCR7 was observed on cell lines both coexpressing or 
lacking CXCR4 (Fig. 3, A and C). In contrast, little or no 
expression of CXCR7 was observed on nontransformed 
adult mouse tissues surveyed as defi  ned by the 125I SDF-1 
binding assay (representative examples out of many are 
shown in Fig. 4 A) or staining by the anti-CXCR7 mAb 
(Fig. 4 B). Interestingly, many of the same nontransformed 
tissues that lacked surface CXCR7 expression expressed 
CXCR7 mRNA (Fig. 4 C), suggesting that CXCR7 can 
be regulated in a posttranslational manner. Collectively, the 
data in Figs. 3 and 4 suggest that membrane CXCR7 pro-
tein is frequently expressed on transformed cells but not on 
normal cells.
Our initial observation of SDF-1 binding to fetal liver 
cells from normal and CXCR4-defi  cient mice (Fig. 1 A) 
suggested that CXCR7 is expressed during normal embry-
onic development. Indeed, the SDF-1 binding site expressed 
by E13 embryos of CXCR4−/− mice was inhibited by 
I-TAC and CCX451 but not by AMD3100 (Fig. 5 A), con-
fi  rming its identity as CXCR7. CXCR7 was found to be 
expressed abundantly during embryonic development, but its 
expression was transitory, being detected on mouse fetal liver 
cells at E11 and E13 but not on E15 and E17 (Fig. 5, A–C). 
This pattern of CXCR7 expression in fetal development was 
demonstrated by ligand binding (Fig. 5 A), antibody staining 
(Fig. 5 B), and Northern blot analysis (Fig. 5 C). Preliminary 
fl  ow cytometric and immunohistochemical analysis suggest 
that this subset of CXCR7 positive cells comprises primitive 
erythrocytes in transit through the liver (unpublished data). 
Further studies are ongoing to characterize this population of 
cells. Interestingly, this loss of CXCR7 expression coincides 
with the lethal consequence of SDF-1 or CXCR4 genetic 
deletion occurring between E15 and E17 (1, 2, 7), suggesting 
that CXCR4 becomes critical in embryonic development at 
a stage when CXCR7 expression diminishes.
Role for CXCR7 in cell survival in vitro
A role of CXCR7 in cell growth/survival was fi  rst indicated 
by an observation that CXCR7-transfected MDA MB 435s 
cells expanded more rapidly in culture than wild-type MDA 
Figure 5.  CXCR7 is expressed in early mouse embryonic development. 
(A) Binding of 125I SDF-1 to embryonic fetal liver (E11–17) in the presence 
of increasing concentrations of SDF-1α, I-TAC, the CXCR7 antagonist 
CCX451, or the CXCR4 antagonist AMD3100. Error bars represent SEM. 
(B) A subset of E13 mouse fetal liver cells stain positive using anti-CXCR7 
antibody 11G8, as indicated by the boxed areas. (C) Northern blot analysis 
shows expression of CXCR7 mRNA in E11 and E13 but not E15 and E17 
fetal liver. Total RNA from CXCR7-positive MCF7 cells and CXCR7-negative 
CEM-NKr cells are included as controls. Data shown were obtained in at 
least fi  ve experiments.JEM VOL. 203, September 4, 2006  2207 
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MB 435s cells, especially in suboptimal tissue culture medium 
(e.g., medium supplemented with only 1% fetal calf serum). 
To explore this phenomenon, both cell types were cultured 
in 1% serum-containing medium for 5 d in replicate culture 
dishes, with separate dishes harvested on each day for cell 
count evaluation. As shown in Fig. 6 A, most wild-type cells 
died during culture in the decreased serum environment 
(continuous line); in contrast, the CXCR7 transfectants ex-
panded exponentially for the fi  rst few days, reaching a plateau 
of live cells by 4–5 d after plating (dashed line). Similar results 
were obtained using several diff  erent CXCR7 transfectant 
lines, as well as wild-type cells that were mock transfected. 
The diff  erence in live cell numbers in cultures of CXCR7 
transfectants versus wild-type lines appeared to refl  ect  in-
creased cell survival rather than increased proliferation of the 
CXCR7 transfected cells, because the total cell recovery of 
transfected and wild-type cells after 5 d of culture was similar 
(Fig. 6 A, right; and Fig. 6 B), whereas the proportion of 
dead cells was dramatically diff  erent (Fig. 6 A, middle; and 
Fig. 6 B). Indeed, use of Annexin V staining to identify apop-
totic cells showed a substantial proportion ( 40%) of apop-
totic cells in wild-type 435s cells after a 5-d culture, whereas 
the CXCR7 transfectant cell culture contained relatively few 
apoptotic cells (Fig. 6 C). The specifi  city of this eff  ect was 
demonstrated by the fact that CXCR7 antagonist CCX754 
could reverse this protection in a dose-related fashion (Fig. 6 D). 
The same compound had no eff  ect on wild-type cells (Fig. 
6 D) or other CXCR7-negative cell lines (unpublished data). 
Collectively these data indicate that expression of CXCR7 
confers a survival advantage to cells that becomes experimen-
tally evident using tissue culture conditions that are subopti-
mal for cell growth.
Role for CXCR7 in cell adhesion in vitro
We additionally tested the ability of CXCR7 to promote ad-
hesion to activated endothelial cell monolayers. Fluorescently 
labeled wild-type MDA MB 435s cells or CXCR7 transfec-
tant cells were applied to human umbilical vein endothelial 
cell (HUVEC) monolayers after stimulation of the endothe-
lium with the activating cytokines TNF-α and IL-1β, and 
adherence was measured by counting fl  uorescent cells (Fig. 7 A) 
or quantitating fl  uorescence (Fig. 7 B). The CXCR7 trans-
fectant adhered to the activated HUVECs markedly more 
than did the wild-type cells (Fig. 7, A and B). Interestingly, the 
Figure 6.  Introduction of CXCR7 into human breast tumor cell line 
MDA MB435s confers a growth advantage to these cells. In all experi-
ments, wild-type or CXCR7-transfected MB435s cells were cultured in vitro 
in media containing a suboptimal concentration of serum (1% instead of 
the standard 10%). (A) Cell counts of live, dead, and total wild-type or 
CXCR7-transfected cells cultured over time. (B) Summary of the day 4 time 
point from growth experiments in histogram form to emphasize the fact 
that the wild-type and CXCR7-transfected cells have similar total cell 
  numbers but are distinguished by how many of these total cells are dead. 
(C) Apoptotic cells in these cultures were identifi  ed (see oval) as cells ex-
cluding propridium iodide and that stained with the Annexin V marker for 
apoptotic cells. (D) CCX754 inhibits CXCR7-mediated growth advantage in 
a dose-dependant manner. Wild-type or CXCR7-transfected cells were incu-
bated with various concentrations of CXCR7 compound throughout assay.2208   A NOVEL SDF-1/I-TAC RECEPTOR INVOLVED IN TUMORIGENESIS | Burns et al.
wild-type line showed some adherence to activated HUVECs, 
and the CXCR7 transfectant showed some adherence to 
  unstimulated HUVECs (Fig. 7 B). In contrast, no adherence 
was observed when wild-type cells were added to unstimu-
lated HUVECs (Fig. 7 B). Similar experiments using a sepa-
rate polyclonal CXCR7-transfected cell line instead of the 
clonal CXCR7-transfected MDA MB 435s cells produced 
similar results (unpublished data). Further insight into the 
possible mechanism of this eff  ect was provided by 125I SDF-1 
binding assays, which revealed that the HUVECs up- regulate 
CXCR7 expression after in vitro stimulation with TNF-α 
and IL-1β (Fig. 7, C and D). Preincubation of the HUVEC 
monolayer with cyclohexamide before TNF-α and IL-1β 
stimulation substantially reduced expression of CXCR7 
Figure 7.  CXCR7 mediates cell adhesion in vitro. Adherence is mea-
sured (A) by capturing a brightfi  eld image to visualize both the HUVEC 
monolayer and the labeled adherent cells (bright circles) and (B) by fl  uo-
rescence to quantitate adhesion. Error bars represent SEM. (C) Activated 
endothelium expresses CXCR7 by radiolabeled binding assay. HUVECs 
were stimulated with TNF-α and IL-1β (HUVEC act.) or sham-treated in 
the presence or absence of cycloheximide (CHX) and incubated with ra-
diolabeled SDF-1. Unlabeled SDF-1α and I-TAC (100 nM each), as well as 
CCX451 and AMD3100 (10 μM each), were examined for the ability to 
compete with 125I SDF-1 binding. (D) Northern blot analysis of CXCR7-
specifi  c mRNA expressed by unstimulated (HUVEC) or TNF-α/IL-1β 
(HUVEC act.) cells cultured in the presence or absence of Cycloheximide 
(CHX). MCF7 (native expression) and CEM-NKr (transfectant) CXCR7 tran-
scripts are shown as controls. Data for A–C were reproduced in at least 
fi  ve experiments. Data for D were obtained twice.
Table I.  Cross-reactivity of CCX754 for other CXCRs
Receptor Affi  nitya Receptor Affi  nity
CCR1 >100 μM CXCR1 >100 μM
CCR2 >100 μM CXCR2 30 μM
CCR3 >100 μM CXCR3 60 μM
CCR4      60 μM CXCR4 >100 μM
CCR5 >100 μM CXCR6 >100 μM
CCR6 >100 μM CX3CR1 90 μM
CCR7 >100 μM
CCR8      90 μM CXCR7 5 nM
CCR9 >100 μM
CCR12 >100 μM
CCX754 is highly selective for CXCR7 inhibition. Data report the concentration of CCX754 required to inhibit specifi  c CXCL binding to the receptors indicated.
aNumbers represent IC50 in radiolabeled binding assays.JEM VOL. 203, September 4, 2006  2209 
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(Fig. 7, C and D), suggesting that the activated HUVECs syn-
thesize new CXCR7 receptors instead of using preexisting 
(but nonbinding) CXCR7 receptors. Increased CXCR7 mRNA 
expression was also observed by Northern blot analysis after 
HUVEC activation (Fig. 7 D). Similar results were obtained 
using endothelial cells derived from lung, heart, and various 
other tissues (unpublished data). Thus, in addition to its marked 
expression in many transformed cells and early fetal liver cells 
(Figs. 3–5), CXCR7 can also be expressed by activated endo-
thelium. Moreover, although expression of CXCR7 on one 
cell type can promote some cell–cell interactions, CXCR7 
expression on both activated HUVECs and tumor cells con-
comitantly produced maximal adherence in vitro.
Effect of CXCR7 antagonism in mouse tumor models
The role of CXCR7 on cell survival and adhesion, coupled 
with the pronounced expression of the receptor on trans-
formed cells and activated endothelial cells, prompted us to 
examine its role in mammalian models of tumor formation. 
To this end, we tested the CXCR7 antagonist CCX754 (14), 
an analogue of CCX451 that has superior in vivo pharmaco-
kinetic properties, in mouse models engrafted with various 
tumors. CCX754’s pharmacokinetic properties permitted 
once daily dosing (Fig. 8 A), bound to CXCR7 with low nM 
affi     nity (Fig. 8 B), and demonstrated high selectivity for 
CXCR7 over other CXCRs (Table I). Effi   cacy of CCX754 
was evaluated in immunodefi  cient or syngeneic mice en-
grafted with either human B lymphoma IM9 (Fig. 9 A), 
  human lung carcinoma A549 (Fig. 9 C), or mouse lung 
carcinoma LL/2 (Fig. 9 D). Each of these tumors was shown 
to express CXCR7 by both the signature 125I SDF-1 binding 
profi  le and fl  ow cytometric staining with the anti-CXCR7 
mAb (unpublished data).
In the fi  rst tumor model, IM9 human B lymphoma cells 
were introduced into the peritoneal cavity of immunodefi  -
cient mice; animals were randomized and treated with either 
CCX754 or an otherwise identical vehicle formulation that 
lacked drug. Levels of CCX754 in sera collected throughout 
the experiment were quantitated by mass spectrometry and 
Figure 8.  Pharmacological properties of CXCR7 antagonist 
(CCX754) used in in vivo experiments. The experiments are shown in 
Fig. 9. (A) Pharmacokinetic properties of CXCR7 antagonist in mice show a 
serum half-life (T1/2) of 6 h, bioavailability of 20% (F), and an acceptable 
liver clearance rate of 30 ml/min/kg (CL). These pharmacokinetic prop-
erties are compatible with once a day dosing in mouse animal models. 
(B) CCX754 inhibits binding of 125I SDF-1 to MCF-7 human breast tumor 
cells with an IC50 of 5 nM. Error bars represent SEM in both panels.
Figure 9.  In vivo effi  cacy of CXCR7 antagonist. Effi  cacy of CCX754 
was evaluated in syngeneic or xenograft mouse models engrafted with 
(A) human B lymphoma IM9 cells, (C) human A549 lung carcinoma cells, 
or (D) mouse LL/2 Lewis lung carcinoma cells. Control groups receiving 
vehicle alone were included in all experiments. Horizontal bars in C indi-
cate means, and error bars in D represent SEM. Images in A show perito-
neal cavity of mice bearing IM9 tumor cells and receiving either CXCR7 
antagonist (right) or vehicle alone (left). (B) Immunohistochemical analy-
sis of CXCR7 expression on a human biopsy sample of a malignant lung 
carcinoma. n = 8 in all groups. Statistical differences between treatment 
groups were calculated using survival curve statistics and the Student’s 
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found to exceed the IC50 of this compound determined in 
binding studies (unpublished data). By day 70, all of the mice 
in the vehicle-treated cohort had succumbed to the tumor 
(Fig. 9 A). In contrast, the cohort receiving CCX754 fared 
signifi  cantly better (P < 0.012), with almost half the cohort 
surviving at 100 d (Fig. 9 A). In a second experiment of this 
type we found that, on necropsy, all the mice treated with 
vehicle had large, encapsulated, vascularized tumors, whereas 
more than half of the animals treated with CCX754 devel-
oped no tumors at all, and those tumors that did form were 
not encapsulated, poorly organized, and frequently had mini-
mal if any vascularization (Fig. 9 A).
We were particularly interested in evaluating the eff  ect of 
our CXCR7 antagonist in animal models of lung cancer, be-
cause we observed in immunohistochemical stains that many 
biopsy samples of primary human lung tumors expressed 
CXCR7 (one example of many shown in Fig. 9 B). To eval-
uate potential effi   cacy of CCX754 in a xenograft lung carci-
noma model, immunodefi   cient mice were implanted 
subcutaneously with fragments of A549 human lung tumor. 
Animals were randomized and treated with either CCX754, 
vehicle alone, or Melphalan as a positive control. At 49 d, 
cohorts receiving either CCX754 or Melphalan exhibited 
  reduced tumor volume as compared with the vehicle control 
group (P < 0.005; Fig. 9 C). In a separate syngeneic tumor 
model, immunocompetent mice were inoculated subcutane-
ously with LL/2 Lewis lung carcinoma cells. Cohorts of mice 
were randomized and treated with either CCX754, vehicle 
alone, or mitomycin C as a positive control. Mice receiving 
the CXCR7 antagonist developed markedly smaller tumors 
than those found in animals receiving vehicle only (P < 0.004; 
Fig. 9 D). Indeed, some tumors were similar in size to those 
in animals receiving the known potent antitumor agent 
  mitomycin C (Fig. 9 D).
DISCUSSION
This study provides extensive characterization of the novel 
high affi   nity SDF-1 (CXCL12)–binding receptor that we re-
ported in an earlier publication (14). The novel receptor, ini-
tially designated CCX CKR2 (14) but renamed CXCR7 in 
this paper, is a 7-transmembrane receptor encoded by RDC1 
(21, 22), a gene that, before our initial report (14), belonged 
to the family of orphan receptors with unknown ligands (20). 
In addition to binding SDF-1, CXCR7 is also a high affi   nity 
receptor for I-TAC (CXCL11) that, before our investiga-
tions, was regarded as a ligand for CXCR3 only. Our data 
show that CXCR7 regulates several important biological 
processes including cell survival, cell adhesion, and tumor de-
velopment in animal models. CXCR7 is expressed on many 
tumor cells but not on most nontransformed cells. Although 
not expressed on unstimulated endothelial cells, CXCR7 can 
be induced, in vitro, on cells that form the neovasculature, a 
fi   nding that is consistent with the independent studies of 
Madden et al., who have observed up-regulation of RDC1 
expression in neovasculature associated with malignant glio-
mas (23). Some of the eff  ects observed have been previously 
associated with SDF-1 activity but have been thought, per-
haps erroneously, to be mediated entirely through CXCR4. 
The elucidation of CXCR7 may require a reexamination of 
much of the previous body of work that presumed a mutually 
exclusive biological interaction between SDF-1 and CXCR4. 
Indeed, suggestions of discrepant CXCR4 expression and 
SDF-1 responsiveness already exist in the literature. For 
  example, previous studies demonstrate that adhesion of E11 
fetal liver cells to bone marrow endothelium can be neutral-
ized by anti–SDF-1 antibodies despite the fact that the E11 
fetal liver cells do not migrate in response to SDF-1 (24).
The gene that encodes CXCR7, RDC1, was initially 
cloned from a dog thyroid cDNA library using degenerate 
PCR primers corresponding to consensus sequences in the 
transmembrane domains of known GPCR (21, 25). Subse-
quent isolation of human and mouse RDC1 homologues 
(22) revealed >90% identity of both nucleotide and protein 
sequences of all three species, indicating an extremely high 
level of evolutionary conservation. RDC1 protein has been 
reported to be a vasoactive intestinal peptide receptor (26) 
and an adrenomedulin receptor (27), but these designations 
have fallen from general acceptance (28–30). RDC1- en-
coded CXCR7 is structurally similar to CXCR2, and the 
CXCR7 gene maps between those of CXCR2 and CXCR4 
on mouse chromosome 1 (22). It is likely that the RDC1/
CXCR7 escaped earlier deorphanization and identifi  cation as 
a CXCR because it lacks certain typical and easily accessible 
functional properties of CXCRs, namely the ability to medi-
ate chemotaxis and calcium mobilization after ligand binding. 
In this context, previous reports of CXCR4−/− mice demon-
strated the absence of SDF-1–induced functional responses 
such as chemotaxis (1, 7) but lacked binding experiments 
with radiolabeled SDF-1 that would have revealed the exis-
tence of the second SDF-1 receptor (i.e., CXCR7). Although 
numerous database search engines suggest that CXCR7/
RDC1 is broadly expressed at the mRNA level (e.g., http://
www.sagenet.org and http://www.symatlas.org; see also 
  references 22, 25), our study demonstrates this is not the case 
at the level of membrane-associated CXCR7. This seeming 
discrepancy is explained by our direct demonstration of cer-
tain nontransformed cells that express CXCR7-specifi  c 
mRNA but lack surface CXCR7 protein as measured by li-
gand binding assays or anti-CXCR7 antibody staining (Fig. 
4). This observation potentially refl  ects some type of post-
translational regulation in CXCR7 expression. Although we 
have observed many examples in which nontransformed cells 
express CXCR7 mRNA but lack surface CXCR7, we have 
seen complete concordance to date in CXCR7 mRNA and 
surface CXCR7 expression in tumor cells, E13 mouse fetal 
liver cells, and activated endothelial cells (Figs. 3, 5, and 7).
The absence of ligand-induced CXCR7-mediated cal-
cium mobilization or cell migration suggests that the CXCR7 
signaling pathway is distinct from the typical GPCR mecha-
nism of other CXCRs. Although an alternative CXCR7-
linked signal transduction pathway has not been identifi  ed in 
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our observations that CXCR7 provides a growth/survival 
advantage and increased adhesiveness of cells (Figs. 6 and 7). 
Indeed, preliminary evidence from microarray analyses sug-
gests that CXCR7 may be constitutively active in tumor cell 
lines, thereby resembling numerous constitutively active non-
CXCR GPCRs (31–33), as well as some virally encoded 
CXCRs; e.g., CMV-encoded US28 (34, 35). The same stud-
ies (31–35) indicate that constitutively active 7TM-GPCRs 
can nevertheless be regulated by receptor-binding ligands via 
a process of inverse agonism rather than by acting as tradi-
tional agonists or antagonists.
Our experiments suggest a potential role for CXCR7 in 
tumor development. In separate experiments, we have sur-
veyed a broad panel of primary human tumors for CXCR7 
expression by immunohistochemistry and found that many 
human tumors, as well as the neovasculature feeding these 
tumors (but not normal blood vessels), express CXCR7 
  (unpublished data). It is not yet clear whether the suppressed 
tumor growth observed in the presence of CXCR7-binding 
small molecules in vivo (Fig. 9) refl   ects action on tumor 
CXCR7, vasculature CXCR7, or both. In support of a di-
rect role for CXCR7 on the tumor cells, we have done an 
extensive series of RNAi experiments showing that 90% re-
duction of CXCR7 expression on two separate tumor lines 
leads to dramatic reduction of in vivo growth of these tu-
mors (unpublished data). We have also observed that intro-
duction of CXCR7 into MDA MB435s cells transforms 
their in vivo growth from exceedingly slow to dramatically 
faster (unpublished data). Although these data implicate the 
importance of tumor-associated CXCR7, they do not ex-
clude an additional role of CXCR7 expressed by neovascu-
lature in tumor development.
Like CXCR4 and CCR5, CXCR7/RDC1 has been 
shown to be a coreceptor for HIV and SIV, in this case strains 
that are neither M- nor T-tropic (36). However, the role of 
CXCR7/RDC1 in the transmission and pathogenesis of HIV 
and SIV remains to be elucidated. A study published in late 
2005 by Balabanian et al. (37) evaluated the shared HIV core-
ceptor function of CXCR4 and RDC1 and found that SDF-
1–induced T cell chemotaxis could be blocked by specifi  c 
antibodies to either CXCR4 or RDC1. Balabanian’s work 
reproduced our fi  nding (14) that both receptors used SDF-1 
ligand; however, a major distinction between their study and 
our own is that SDF-1 binding to CXCR7 caused T cell che-
motaxis in their hands, whereas we have not observed RDC1-
mediated chemotaxis of any cell tested to date, including 
primary T cells (unpublished data). Furthermore, we have not 
detected surface CXCR7 on mouse or human T cells, either 
by radiolabeled SDF-1 binding analyses or CXCR7-specifi  c 
mAb binding (unpublished data). The basis of the discrepant 
observations of Balabanian’s study and our own is currently 
unknown and warrants further investigation.
In conclusion, CXCR7 is a new CXCR with properties 
that aff  ect a spectrum of important biological and pathological 
processes, including cell growth/survival and adhesion, as 
well as the promotion of tumor growth. Our data suggest that 
the homeostatic and infl  ammatory events regulated by SDF-1 
and I-TAC are much more complex than previously thought 
and that reinterpretation of earlier fi  ndings related to these 
chemokines in light of fi   nding an additional high affi   nity 
  receptor for them may be warranted. CXCR7 may provide a 
new molecular link in the chain of connections between in-
fl  ammation and cancer, and in this context the interrelation-
ships between CXCR7, CXCR4, CXCR3, and their shared 
chemokines, SDF-1 and I-TAC, will be of considerable in-
terest. Finally, the elucidation of this new receptor may intro-
duce new avenues of potential therapeutic intervention in 
important clinical indications, including oncology.
MATERIALS AND METHODS
Reagents and cells. Chemokines were obtained from R&D Systems and 
PeproTech. 125I SDF-1 and 125I I-TAC were purchased from PerkinElmer 
and GE Healthcare, respectively. mAbs used in fl  ow cytometry, anti-
CXCR4 (clone 12G5) and normal mouse IgG2a, were obtained from R&D 
Systems. Goat anti–mouse IgG PE conjugate (Coulter Immunotech) was 
used to detect antibody binding. Unless otherwise indicated, cell lines were 
obtained from the American Type Culture Collection. CEM-NKr cells 
were obtained from the National Institutes of Health AIDS Research and 
Reference Reagent Program. HUVECs were purchased from Clonetics. 
Human PBMCs were collected from buff  y coats of healthy donors (Stanford 
Blood Center), as described previously (38). Primary mouse cells were 
  prepared from harvested organs by mechanical dispersion through a 70-μm 
nylon strainer.
Mice. 8-wk-old female C57BL/6 mice, SCID mice, and timed-pregnant 
C57BL/6 mice were purchased from Charles River Laboratories. All ani-
mal procedures and studies were performed in strict accordance with pro-
tocols approved by the ChemoCentryx, Inc. institutional animal care and 
use committee.
Radioligand binding assays. Assays to assess radioligand binding to 
CXCR7 were performed as previously described (16). Radioligand binding 
was quantitated by analyzing the cells in a γ counter (PerkinElmer). Data 
were analyzed and plotted using software (Prism; GraphPad).
Calcium mobilization. Calcium mobilization responses were performed 
as described previously using Indo-1, an intracellular ratiometric fl  uores-
cent dye (38).
Cell migration. Cell migration assays were performed using a 96-well 
  microchamber (Chemo Tix; NeuroProbes, Inc.). Cells were resuspended in 
chemotaxis buff  er (HBSS with Ca2+, Mg2+, and 0.1% BSA) and placed on 
top of the filter (pore size of 3 or 5 μm, depending on cell size). Che-
mokines were placed in chamber below the fi  lter. After 90 min at 37°C in a 
humidifi  ed incubator, fi  lters were removed, 5 μl of CyQuant (Invitrogen) 
was added to the lower chamber, and the microplate was analyzed on a plate 
reader (Molecular Devices) at 540-nm wavelength.
Flow cytometry. Cells were labeled using standard procedures and ana-
lyzed on a FACScan (Becton Dickinson). The data presented are gated for 
viable cells using light scatter.
CXCR7 transfectants. The complete coding sequence of the gene encod-
ing human CXCR7, RDC1, was isolated from MCF-7 cells using an 
mRNA isolation kit (μMACs; Miltenyi Biotec). DNA contamination was 
removed by DNase digestion on RNeasy columns (QIAGEN), and cDNA 
was generated using an RNA PCR core kit (GeneAmp; Applied Biosys-
tems). PCR of cDNA samples was performed with Taq PCR Master 
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(hRDC1F, 5′-G  A  A  T  G  C  G  G  C  C  G  C  T  A  T  G  G  A  T  C  T  G  C  A  T  C  T  C  T  T  C  G  A-
C  T  -3′; hRDC1R, 5′-G  A  A  T  G  C  G  G  C  C  G  C  T  C  A  T  T  T  G  G  T  G  C  T  C  T  G  C  T-
C  C  A  A  G  -3′). NotI-digested PCR products were ligated into NotI-digested 
pcDNA3.1(+) (Invitrogen) and screened for orientation, then the cDNA 
sequence was confi  rmed. Plasmid DNA was isolated from overnight bacte-
rial cultures by Maxiprep (QIAGEN). 10 μg Plasmid DNA was added to 
MDA MB 435s cells via electroporation (0.22 kV, 960 uF) using a Gene 
Pulser (Bio-Rad Laboratories). 48 h after electroporation, cells were trans-
ferred to selection medium (1,000 μg/ml G418).
mAb production. mAbs to human CXCR7 were obtained by DNA vac-
cination using an RDC1-containing plasmid. CXCR7-specifi  c antibodies 
were identifi  ed by binding to human RDC1 transfectants versus transfectants 
expressing an irrelevant protein. Two CXCR7 specifi  c antibodies desig-
nated 11G8 and 6E10 were generated. Specifi  city was confi  rmed by a lack 
of reactivity to a panel of chemokine receptors.
Antibody purifi  cation. Antibodies were purifi  ed from harvested superna-
tants using protein G columns with subsequent acidic elution (glycin, pH 3) 
and dialysis against PBS. Antibody concentration was determined by Lowry 
assay against BSA.
Northern blot analyses. 10 μg total RNA was subjected to electrophore-
sis, transferred to nitrocellulose fi  lters, and probed using reagents (Northern-
Max; Ambion). Specifi  c antisense riboprobes were generated from cloned 
mouse or human CXCR4 and CXCR7 open reading frames using an RNA 
kit (Strip-EZ; Ambion). The FirstChoice Mouse Blot 1 (Ambion) was pur-
chased and probed with mouse CXCR4 and CXCR7 riboprobes.
Cell apoptosis assay. Annexin V–FITC (Invitrogen) and propidium io-
dide (Invitrogen) were added to washed cells (106 cells/ml in FACS buff  er) 
for 15 min at room temperature in the dark. FACS buff  er was added, and 
cells were analyzed immediately by fl  ow cytometry.
Adhesion assay. HUVECs were allowed to adhere to 24-well plastic tissue 
culture plates overnight. The monolayer was treated with medium containing 
10 ng/ml TNF-α and 10 ng/ml IL-1β for 5 h. Cells were loaded with calcein 
AM (Invitrogen) in PBS for 30 min at room temperature, washed, and added 
to the HUVEC monolayers for 15 min at 37°C. Adherent cells were quanti-
tated by microscopy and by fl  uorescence intensity.
In vivo tumor models. In the syngeneic model, C57BL/6 mice were in-
oculated with the mouse Lewis lung carcinoma line LL/2. In the xenograft 
model, CB17 SCID mice were inoculated with IM9 human lymphoma or 
transplanted with A549 human lung carcinoma fragments. In all experi-
ments, s.c. treatment with CXCR7 antagonist (100 mpk qd) or vehicle 
(equivalent volume) commenced at the time of tumor transplantation. Posi-
tive control groups received known chemotherapeutic agents (either mito-
mycin or melphalan) administered at 2 mg/kg intraperitoneally every 2 d.
Immunohistochemistry. 5-μm sections of formalin-fi  xed,  paraffi   n-
  embedded human or mouse spleen were deparaffi   nized, hydrated, and 
exposed to anti-CXCR7 mAb clone 11G8 at 10 μg/ml for 1 h. Rinsed 
slides were exposed to biotin-conjugated Fab′2 fragments of goat anti–mouse 
IgG for 30 min. The slides were rinsed and exposed to avidin-biotinylated 
alkaline phosphatase complex for 20 min. The slides were rinsed, exposed to 
fuchsin+ substrate for 5–20 min, and rinsed with deionized water. The slides 
were counterstained in Mayer’s hematoxylin for 3 min, rinsed with tap wa-
ter, and mounted with coverslips.
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